surmount-1 tirzepatide trial obesity without diabetes (NEJM 2022) tested — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants Tirzepatide and blood pressure reduction:

Through appetite suppression, delayed gastric emptying, and central nervous system effects on food reward pathways, these drugs cause significant weight loss

Our results indicate that clinically used type 2 diabetes treatments could be employed in a preventive role to improve stroke outcome by exerting dual pharmacological action: weight loss and acute neuroprotection

Nissen says

If you find them unmanageable call your doctor for medical advice about side effects

Other concerning risks include intestinal blockages, pancreatitis, and rare but severe gallbladder complications such as cholecystitis (inflammation)

They will require prior authorization from a licensed healthcare provider